MedPath

Rate Ventricular Control Therapy in Patients With Permanent Atrial Fibrillation

Phase 3
Conditions
Atrial Fibrillation
Interventions
Device: implantable continuous monitor
Registration Number
NCT01444573
Lead Sponsor
Meshalkin Research Institute of Pathology of Circulation
Brief Summary

The investigators hypothesized that very lenient rate control is not inferior to strict or lenient rate control assessed by implantable continuous ECG monitor for preventing cardiovascular hospitalization and mortality in patients with long-standing persistent or permanent atrial fibrillation

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
90
Inclusion Criteria
  • Long-standing persistent or permanent atrial fibrillation
  • Mean resting heart rate > 80 beats per minute with or without rate control medication
  • Age < 70 years old
  • Constant use of anticoagulation therapy
Exclusion Criteria
  • Paroxysmal or persistent atrial fibrillation
  • Non-stable heart failure or > III NYHA FC
  • Indications for IPG/CRT/ICD
  • Thyroid dysfunction
  • Inability to walk or bike.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Group 2 (Lenient control <120bpm)implantable continuous monitor-
Group 1 (Strict control <80 bpm)implantable continuous monitor-
Primary Outcome Measures
NameTimeMethod
Hospitalization for all cardio-vascular events12 months
Secondary Outcome Measures
NameTimeMethod
stroke12 months
life-threatening arrhythmic and drugs adverse events12 months
All-cause death12 months

Trial Locations

Locations (1)

State Research Institute of CIrculation Pathology Novosibirsk, Russian Federation

🇷🇺

Novosibirsk, Russian Federation

© Copyright 2025. All Rights Reserved by MedPath